SCHEMBL25429481

SCHEMBL25429481

Nc1ccc(-c2cc(C3CC3)[nH]n2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 5/20 0.47
MKNK2 Q9HBH9 5/20 0.47
HCAR2 Q8TDS4 2/20 0.45
HCAR3 P49019 1/20 0.45
IGF1R P08069 2/20 0.41
DRD4 P21917 4/20 0.41
DRD2 P14416 3/20 0.41
DRD3 P35462 3/20 0.41
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPK1 P28482 1/20 0.39
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38
S1PR2 O95136 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
ALOX12 P18054 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25431152 0.79 MKNK1 (0.59) MKNK1MKNK2HCAR2HCAR3DRD4
SCHEMBL25339487 0.76 MAPT (0.45) MKNK1MKNK2HCAR2HCAR3IGF1R
SCHEMBL27421814 0.72 MEN1 (0.54) MKNK1MKNK2HCAR2HCAR3DRD4
SCHEMBL29758358 0.71 CA12 (0.46) KMT2AMEN1MAPTSMN1; SMN2POLB
SCHEMBL29374702 0.71 CA12 (0.46) KMT2AMEN1MAPTSMN1; SMN2POLB
SCHEMBL1069905 0.71 CA12 (0.46) KMT2AMEN1MAPTSMN1; SMN2POLB
SCHEMBL4457723 0.70 HCAR2 (0.43) MKNK1MKNK2HCAR2HCAR3KMT2A
SCHEMBL30558789 0.70 MKNK1 (0.54) MKNK1MKNK2HCAR2HCAR3ROCK2
SCHEMBL27977175 0.70 MKNK1 (0.54) MKNK1MKNK2HCAR2HCAR3ROCK2
SCHEMBL28820147 0.69 HCAR2 (0.49) MKNK1MKNK2HCAR2HCAR3IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136559-A1 SMO MODULATOR COMPOUNDS Omass Therapeutics Limited (GB) 2025-05-01 US disclosed
EP-4472959-A1 SMO MODULATOR COMPOUNDS Omass Therapeutics Limited (GB) 2024-12-11 EP disclosed
WO-2023148481-A1 SMO MODULATOR COMPOUNDS Omass Therapeutics Limited (GB) 2023-08-10 WO disclosed
WO-2023148481-A1 SMO MODULATOR COMPOUNDS Omass Therapeutics Limited (GB) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136559-A1 SMO MODULATOR COMPOUNDS SMO, SHH, GLI1 MKNK1 1943/4885MKNK2 1543/4885HCAR2 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.